Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 27;13(23):7186.
doi: 10.3390/jcm13237186.

Efficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis

Benedetto Neri  1 , Roberto Mancone  1 , Mariasofia Fiorillo  1 , Sara Concetta Schiavone  1 , Stefano Migliozzi  1 , Livia Biancone  1
Affiliations
Review

Efficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis

Benedetto Neri et al. J Clin Med. .

Abstract

Background: Janus kinase-inhibitors (JAK-i) have recently been approved for treating patients with Ulcerative Colitis (UC); therefore, further information is needed, particularly regarding efficacy and safety. Objectives: To provide a comprehensive review regarding the efficacy and safety of currently available JAK-i in UC. Methods: The PubMed and Scopus databases were considered, searching for 'JAK', 'JAK-inhibitor', 'Janus Kinases', 'Tofacitinib', 'Filgotinib', 'Upadacitinib', individually or in combination with 'IBD', 'Ulcerative Colitis', 'safety', 'efficacy', 'study' and 'trial'. The search was focused on full-text papers published in English, with no publication date restrictions. Results: The efficacy and safety of JAK-i approved for treating patients with UC have been summarized. These included Tofacitinib, Filgotinib and Upadacitinib. Findings from both clinical trials and real-life studies in UC were reported, with particular regard to their efficacy in inducing clinical response and remission, steroid-free remission and endoscopic and histological healing. Overall, JAK-i proved to be effective and safe in selected subgroups of patients with UC. The rapid onset of action and the oral route of administration represent the most relevant characteristics of these drugs. Safety concerns using Tofacitinib in subgroups of patients (infections, hypercholesterolemia, venous thromboembolism and cardiovascular events) were initially raised. More recently, all JAK-i for UC showed an overall satisfactory safety profile. However, indication should be carefully given. Conclusions: The use of JAK-i UC is promising, although no predictive markers of response are currently available. Optimizing their use, as monotherapy or combined with other immunomodulators, may increase their efficacy in appropriately selected subgroups of patients with UC.

Keywords: Filgotinib; JAK inhibitors; Tofacitinib; Ulcerative Colitis; Upadacitinib; efficacy; safety; small molecules.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Ungaro R., Mehandru S., Allen P.B., Peyrin-Biroulet L., Colombel J.F. Ulcerative colitis. Lancet. 2017;389:1756–1770. doi: 10.1016/S0140-6736(16)32126-2. - DOI - PMC - PubMed
    1. Torres J., Billioud V., Sachar D.B., Peyrin-Biroulet L., Colombel J.F. Ulcerative colitis as a progressive disease: The forgotten evidence. Inflamm. Bowel. Dis. 2012;18:1356–1363. doi: 10.1002/ibd.22839. - DOI - PubMed
    1. Nakase H., Sato N., Mizuno N., Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun. Rev. 2022;21:103017. doi: 10.1016/j.autrev.2021.103017. - DOI - PubMed
    1. Kobayashi T., Siegmund B., Le Berre C., Wei S.C., Ferrante M., Shen B., Bernstein C.N., Danese S., Peyrin-Biroulet L., Hibi T. Ulcerative colitis. Nat. Rev. Dis. Primers. 2020;6:74. doi: 10.1038/s41572-020-0205-x. - DOI - PubMed
    1. Shapiro J.M., Zoega H., Shah S.A., Bright R.M., Mallette M., Moniz H., Grabert S.A., Bancroft B., Merrick M., Flowers N.T., et al. Incidence of Crohn’s disease and ulcerative colitis in Rhode Island: Report from the Ocean State Crohn’s and Colitis Area Registry. Inflamm. Bowel. Dis. 2016;22:1456–1461. doi: 10.1097/MIB.0000000000000745. - DOI - PMC - PubMed

LinkOut - more resources